Unlock instant, AI-driven research and patent intelligence for your innovation.
Double-aryl maleimide compound, pharmaceutically acceptable salt thereof, method for preparing double-aryl maleimide compound and pharmaceutically acceptable salt and application of double-aryl maleimide compound and pharmaceutically acceptable salt
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A maleimide and compound technology, applied in the field of bisarylmaleimide compounds, can solve problems such as tumors and activity decline
Inactive Publication Date: 2016-07-20
ZHEJIANG UNIV OF TECH +1
View PDF2 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
The above two reasons will make some dioxygenases dependent on α-KG include prolylhydroxylase (prolylhydroxylase, PHD), DNA hydroxylase Tet family and histonelysine demethylases (histonelysinedemethylases, KDMs) and other activities decreased, eventually leading to the occurrence of tumors
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0028] Example 1: 1-methyl-3-(tributyltinyl)-1H-pyrazol[3,4-b]pyridine (2a)
[0029] Add 2.0g (4.9mmol) 3-(tributyltinyl)-1H-pyrazol[3,4-b]pyridine and 30mL anhydrous DMF into the three-necked flask, control the temperature at 0-5°C, and add 0.22g in batches (5.5mmol) 60% NaH, after adding, keep stirring for 30min, then dropwise add 0.84g (5.9mmol) methyl iodide, react at 0~5°C for 1h after dropping, then rise to room temperature for 0.5h, after the reaction, put The reaction solution was poured into 600mL water, extracted with dichloromethane (50mL×3), the organic layers were combined, washed with saturated brine (150mL×3), dried over anhydroussodiumsulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column Purification by analysis (petroleumether: ethyl acetate = 6:1, v / v) gave 1.56 g of oil 2a with a yield of 75.5%. 1 HNMR (CDCl 3 )δ:0.89(9H,t,J=7.5Hz),1.21-1.26(6H,m),1.33-1.38(6H,m),1.58-1.63(6H,m),4.19(3H,...
Embodiment 2
[0030] Example 2: 1-Ethyl-3-(tributyltinyl)-1H-pyrazol[3,4-b]pyridine (2b)
[0031] The synthesis method is the same as that in Implementation 1, except that ethyl bromide is used instead of methyl iodide to obtain oil 2b, yield: 62.3%, 1 HNMR (CDCl 3 )δ:0.89(9H,t,J=7.5Hz),1.22-1.27(6H,m),1.34-1.40(6H,m),1.54(3H,t,J=7.5Hz),1.57-1.64(6H ,m),4.63(2H,q,J=7.5Hz),7.04-7.07(1H,m),8.00(1H,dd,J=8.0,1.5Hz),8.50(1H,dd,J=4.5,1.5 Hz).
Embodiment 3
[0032] Example 3: 1-Butyl-3-(tributyltinyl)-1H-pyrazol[3,4-b]pyridine (2c)
[0033] The synthetic method is the same as that in Implementation 1, except that methyl bromide is used instead of methyl iodide to obtain oil 2c with a yield of 58.3%. 1 HNMR (CDCl 3 )δ:0.89(9H,t,J=7.5Hz),0.95(3H,t,J=7.5Hz),1.20-1.29(8H,m),1.32-1.39(8H,m),1.56-1.63(6H ,m),4.57(2H,t,J=7.5Hz),7.03-7.08(1H,m),8.01(1H,dd,J=8.0,1.5Hz),8.50(1H,dd,J=4.5,1.5 Hz).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a double-arylmaleimide compound, pharmaceutically acceptable salt thereof, a method for preparing the double-arylmaleimide compound and the pharmaceutically acceptable salt and application of the double-arylmaleimide compound and the pharmaceutically acceptable salt. The double-aryl maleimide compound and the pharmaceutically acceptable salt can be particularly used as isocitrate dehydrogenase 1 (IDH1) mutant inhibitors and can be applied to treating malignant tumor such as glioma and acute myeloid leukemia. The double-aryl maleimide compound, the pharmaceutically acceptable salt, the method and the application have the advantages that the double-aryl maleimide compound has efficiently selective IDH1 mutant inhibitory activity, and accordingly the double-aryl maleimide compound and the pharmaceutically acceptable salt can be used for treating the IDH1 mutant mediated malignant tumor such as the glioma and the acute myeloid leukemia; the double-aryl maleimide compound, the pharmaceutically acceptable salt and the method are reasonable in design, and the method is simple and practical.
Description
technical field [0001] The present invention mainly relates to a kind of bisarylmaleimide compound and its pharmaceutically acceptable salt as well as its preparation method and application. Application in the treatment of malignant tumors such as glioma and acute myeloid leukemia mediated by IDH1 mutation. Background technique [0002] Malignant tumors are one of the major diseases that threaten human health. Worldwide, 8.5 million people died of cancer in 2008, and according to current trends, by 2020 it is expected that there will be 20 million new cancer cases, of which the death toll will reach 12 million. The prevention and treatment of tumors has become an important research topic in the medical circles of various countries. Although people have a deeper understanding of the cause and development of tumors, and a large number of anti-tumor drugs are used clinically. However, these widely used antitumor drugs often have problems such as high toxicity and side effect...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More